Skip to main content
logo
Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
34.19
-0.41 (-1.18%)
At close: Aug 28, 2026, 4:00 PM EDT
33.91
-0.28 (-0.82%)
After-hours: Aug 28, 2026, 7:58 PM EDT

Vera Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
153.89100.224123.7921.9111.92
Research & Development
261.87215.26126.1778.2368.9922.48
Operating Expenses
415.76315.47167.17102.0190.934.4
Operating Income
-415.76-315.47-167.17-102.01-90.9-34.4
Interest Expense
-7.54-7.53-7.63-3.79-0.99-0.02
Interest & Investment Income
22.9624.4820.717.981.750.02
Other Non Operating Income (Expenses)
-0.56-0.091.941.831.9-
EBT Excluding Unusual Items
-400.89-298.61-152.15-95.99-88.25-34.41
Gain (Loss) on Sale of Investments
-----0.81-0.89
Gain (Loss) on Sale of Assets
-----2.69
Other Unusual Items
-1-1----
Pretax Income
-401.89-299.61-152.15-95.99-89.06-32.61
Income Tax Expense
000000
Net Income
-401.9-299.62-152.15-95.99-89.06-32.61
Net Income to Common
-401.9-299.62-152.15-95.99-89.06-32.61
Net Income Growth
------
Shares Outstanding (Basic)
686455432713
Shares Outstanding (Diluted)
686455432713
Shares Change
12.23%16.10%29.55%60.73%97.76%4099.14%
EPS (Basic)
-5.89-4.66-2.75-2.25-3.35-2.43
EPS (Diluted)
-5.89-4.66-2.75-2.25-3.35-2.43
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-338.91-241.73-135.65-92.24-67.66-23.71
Free Cash Flow Per Share
-4.97-3.76-2.45-2.16-2.55-1.76
EBITDA
-415.22-315.01-167.07-101.99-90.73-34.23
D&A For EBITDA
0.540.470.110.020.180.18
EBIT
-415.76-315.47-167.17-102.01-90.9-34.4
SEC Filings: 10-K · 10-Q